Skip to main
CAPR
CAPR logo

Capricor Therapeutics (CAPR) Stock Forecast & Price Target

Capricor Therapeutics (CAPR) Analyst Ratings

Based on 10 analyst ratings
Strong Buy
Strong Buy 70%
Buy 30%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Capricor Therapeutics Inc. is advancing its clinical-stage biotechnology initiatives, particularly with deramiocel, a cell therapy currently in Phase 3 development for Duchenne muscular dystrophy (DMD). The favorable long-term benefit-risk profile of deramiocel, coupled with a partnership that enhances manufacturing capabilities and commercial preparation, positions the company for potential market entry in both the U.S. and Europe. The ongoing success of the HOPE-2 OLE study further supports optimism regarding the therapy's efficacy and safety, validating its transformative potential in addressing unmet medical needs in DMD treatment.

Bears say

Capricor Therapeutics is facing a negative outlook mainly due to the mixed clinical trial results for its product deramiocel, which showed a decline in the Performance of the Upper Limb 2.0 (PUL 2.0) score, indicating limited efficacy compared to the external comparator group. Additionally, the company's reliance on a series of successful clinical trials and the ability to secure necessary funding to advance its drug development is a significant concern, as any failures or inconclusive results could impede progress and investor confidence. Furthermore, the observed decline in disease progression over the trial years is marginal, raising doubts about the long-term viability of the therapies under development.

Capricor Therapeutics (CAPR) has been analyzed by 10 analysts, with a consensus rating of Strong Buy. 70% of analysts recommend a Strong Buy, 30% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Capricor Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Capricor Therapeutics (CAPR) Forecast

Analysts have given Capricor Therapeutics (CAPR) a Strong Buy based on their latest research and market trends.

According to 10 analysts, Capricor Therapeutics (CAPR) has a Strong Buy consensus rating as of Aug 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23.70, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23.70, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Capricor Therapeutics (CAPR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.